Psychosis Clinical Trials for Alzheimer’s Disease

Together, we are exploring new possibilities to help improve everyday life for patients and bring hope to families.

Psychosis can be one of the most challenging symptoms experienced by individuals living with Alzheimer’s disease and related dementias. It can cause distress, confusion, and fear for both patients and their caregivers. Through our ongoing clinical research studies, we are working to better understand and evaluate potential treatments that may help reduce psychosis symptoms and improve day-to-day quality of life.

If you or a loved one has been experiencing symptoms of psychosis associated with Alzheimer’s for at least one month, you may be eligible to participate in one of our research studies.

What is “Psychosis” in Alzheimer’s?

Psychosis affects how a person perceives or interprets reality. While not everyone with Alzheimer’s will experience psychosis, it is a common symptom that can occur as the disease progresses.

Symptoms may include:

• Hallucinations: Seeing, hearing, or sensing things that are not present.
• Delusions: Strong beliefs that are not based in reality, such as believing someone is stealing from them or trying to harm them.
• Increased Suspicion or Fear: Feeling unusually worried, mistrustful, or anxious.
• Misidentification: Confusing familiar people, places, or objects for something else.

These symptoms may come and go, and they can significantly affect a person’s comfort, safety, and emotional well-being.

Our Goal

Our goal is to develop better treatment options that can help individuals with Alzheimer’s experience fewer psychosis symptoms, greater emotional stability, and an improved quality of life.

Every participant plays an important role in advancing research and helping shape the future of dementia care.

About the Studies and Medication

Our psychosis studies are evaluating investigational approaches aimed at reducing behavioral and emotional symptoms associated with Alzheimer’s.

Researchers are studying medications that are FDA-approved for other conditions or have demonstrated safety in previous clinical use. These studies are designed to determine whether these treatments may also help reduce psychosis symptoms and improve overall well-being in individuals with Alzheimer’s.

Participant safety is closely monitored throughout the study by qualified medical and research professionals.

What to Expect

If you choose to participate, the study may include:

• Scheduled clinic visits and phone check-ins.
• A physical exam and an electrocardiogram (ECG).
• Blood and urine samples.
• Brain imaging (MRI or CT scan, if not completed within the past 5 years).

Transportation and parking stipends are available.

Participation is voluntary, and you may leave the study at any time.

Who Can Participate?

You or your loved one may qualify to participate if you:

• Are 55 to 90 years old.
• Have been diagnosed with Alzheimer’s.
• Have experienced symptoms of psychosis for at least one month.
• Have a caregiver who can attend all study visits.
• Are willing to participate in both in-person visits and phone check-ins.

A member of our research team will review the study criteria and answer any questions you may have during the screening process.

Why Participate?

By participating in a clinical trial, you can help researchers learn more about new treatment approaches for psychosis in Alzheimer’s while contributing to future advances in care.

Potential benefits of participation may include:

• Access to study-related care and evaluations.
• Close monitoring by experienced research professionals.
• The opportunity to contribute to scientific discoveries that may benefit others living with Alzheimer’s.
• Helping researchers better understand symptoms and treatment options for Alzheimer’s-related psychosis.

Meet Your Clinical Research Team

Antonio L. Teixeira, MD, PhD